000			01839 a2200457 4500
005			20250514230544.0
264		0	_c20050630
008			200506s 0 0 eng d
022			_a0022-3018
024	7		_a10.1097/01.nmd.0000165292.11527.16 _2doi
040			_aNLM _beng _cNLM
100	1		_aMiller, Edward Alan
245	0	0	_aIncidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. _h[electronic resource]
260			_bThe Journal of nervous and mental disease _cJun 2005
300			_a387-95 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdult
650	0	4	_aAntipsychotic Agents _xadverse effects
650	0	4	_aBenzodiazepines _xadverse effects
650	0	4	_aClozapine _xadverse effects
650	0	4	_aDiabetes Mellitus _xchemically induced
650	0	4	_aDibenzothiazepines _xadverse effects
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aIncidence
650	0	4	_aInsurance Coverage _xstatistics & numerical data
650	0	4	_aMale
650	0	4	_aMental Disorders _xdrug therapy
650	0	4	_aOlanzapine
650	0	4	_aProportional Hazards Models
650	0	4	_aQuetiapine Fumarate
650	0	4	_aRisk Factors
650	0	4	_aRisperidone _xadverse effects
650	0	4	_aSex Factors
650	0	4	_aUnited States _xepidemiology
700	1		_aLeslie, Douglas L
700	1		_aRosenheck, Robert A
773	0		_tThe Journal of nervous and mental disease _gvol. 193 _gno. 6 _gp. 387-95
856	4	0	_uhttps://doi.org/10.1097/01.nmd.0000165292.11527.16 _zAvailable from publisher's website
999			_c15581761 _d15581761